The Evaluation of serum Nestin and HOTAIR rs12826786 C>T polymorphism as screening tools for Breast cancer in Egyptian women
Serum Nestin and Breast Cancer
Abstract
Nestin; a neural stem cell protein that plays an important role in Cancer stem cells (CSC) development and proliferation. It has been identified as a marker for newly formed endothelial cells and was shown to be preferentially expressed in basal and myoepithelial cells of the mammary gland. HOTAIR is long intergenic non-coding (linRNA) associated with tumorigenesis through promotion of epithelial – mesenchymal transition (EMT) and stemness as well. HOTAIR gene contains a functioning single nucleotide polymorphic site rs12826786 C>T that has been associated with several cancer types.
We evaluated serum Nestin and the HOTAIR rs12826786 C>T polymorphism, in healthy and breast cancer Egyptian women, for using as a possible screening tool to identify patients with breast cancer. Also, we tested the possible association of the two markers with each other and aggressiveness of the disease.
Results: Patients with breast cancer had a median (Min-Max) of serum Nestin 31.3 (6.7 - 167.3 pg/ml) while control subjects had a median (Min-Max) of serum Nestin 42.3 ( 25.7-315.95) pg/ml
The best cut-off value for serum Nestin to differentiate normal subjects and patients with breast cancer was 39.9 pg/ml. This cut-off value had a diagnostic sensitivity of 84.8% and specificity of 65.1%.
There was a significant difference in the distribution of different alleles in patients with breast cancer than normal subjects (P= 0.039 Exact Fisher test)
The breast cancer patients group had 23% CC, 52.1%CT and 23.9% TT genotypes respectively while the control group had 46.9% CC, 42.8%CT and 10.2% TT respectively.
Conclusion: A significantly low serum Nestin below 39.9 pg/ml and higher percentage of the T/T homozygous mutant allele of HOTAIR rs12826786 C>T were found in Egyptian patients with breast cancer. We suggest that the reported cutoff value of serum Nestin and the presence of C/T polymorphism can be used to assess the risk of females for developing breast cancer and might be of potential benefit in screening the disease. Larger studies in different ethnic groups are needed to confirm our findings.
References
Ahmad A1.Breast Cancer Statistics: Recent Trends. Adv Exp Med Biol. 2019;1152:1-7.
Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E2.European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019;30:781-787.
Qaseem A, Lin JS, Mustafa RA, Horwitch CA, Wilt TJ; Clinical Guidelines Committee of the American College of Physicians. Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. Ann Intern Med. 2019;170:547-560.
Mack DS, Lapane KL. Screening Mammography Among Older Women: A Review of United States Guidelines and Potential Harms. J Womens Health (Larchmt). 2019;28:820-826.
Roberts-Klein S1, Iuanow E, Slanetz PJ.Avoiding pitfalls in mammographic interpretation. Can Assoc Radiol J. 2011;62:50-9.
Nazari SS1, Mukherjee P2.An overview of mammographic density and its association with breast cancer. Breast Cancer. 2018;25:259-267.
Miglioretti DL, Lange J, van den Broek JJ, Lee CI, van Ravesteyn NT, Ritley D, et al. Radiation-Induced Breast Cancer Incidence and Mortality from Digital Mammography Screening: A Modeling Study. Ann Intern Med. 2016;164:205-14.
Svobodova S, Kucera R, Fiala O, Karlikova M, Narsanska A, Zedníková , Treska V, Slouka D, Rousarova M, Topolcan O, Finek J.CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer. Anticancer Res. 2018;38:465-469.
Michalczyk K and Ziman M. Nestin structure and predicted function in cellular cytoskeletalorganisation. Histol Histopathol 2005; 20:665–671.
Krupkova O Jr, Loja T, Zambo I, et al. Nestin expression in human tumors and tumor cell lines.Neoplasma 2010; 57: 291–298.
Neradil J and Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci 2015; 106: 803–811.
Han S, Huang T, Wu X, Wang X, Li W, Liu S, Yang W, Shi Q, Li H,Shi K, Hou F. Prognostic value of ALDH1 and Nestin in advanced cancer: a systematic meta-analysis with trial sequential analysis. Ther Adv Med Oncol. 2019 ;11:1758835919830831. doi: 10.1177/1758835919830831. eCollection 2019.
Krüger, K. et al. Microvessel proliferation by co-expression of endothelial Nestin and Ki-67 is associated with a basal-like phenotype
and aggressive features in breast cancer. The Breast.2013; 22, 282–288.
Dusart P, Fagerberg L, Perisic L, Civelek M, Struck E, Hedin U, Uhlén M, Trégouët DA, Renné T, Odeberg J, Butler LM. A systems-approach reveals human Nestin is an endothelial-enriched, angiogenesis-independent intermediate filament protein. Sci Rep. 2018;8:14668
Lancaster JM, Carney ME, Futreal PA. BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer. Medscape Women’s Health. 1997;2:7.
Thorat MA, Balasubramanian R. Breast cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2019; 19, 30170-1.
Zhang P, Tillmans LS, Thibodeau SN, Wang L. Single-Nucleotide Polymorphisms Sequencing Identifies Candidate Functional Variants at Prostate Cancer Risk Loci. Genes 2019, 10, 547. pii: E547. doi: 10.3390/genes10070547.
Zheng L, Li X, Gu Y, Lv X, Xi T. The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1. Breast Cancer Res Treat. 2015; 150:105-18.
Carninci P, Hayashizaki Y. Noncoding RNA transcription beyond annotated genes. Curr Opin Genet Dev. 2007;17:139–144.
Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:37.
Tang Q, Hann SS. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer. Cell Physiol Biochem 2018;47:893-913.
Bhan A, Mandal SS. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. Chem Med Chem 2014 Sep;9:1932-56.
Pádua Alves C, Fonseca AS, Muys BR, de Barros E Lima Bueno R, Bürger MC, de Souza JE, et al. Brief report: The lincRNA HOTAIR is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells. 2013;31:2827-32.
Lu MY, Liao YW, Chen PY, Hsieh PL, Fang CY, Wu CY, et al. Targeting LncRNA HOTAIR suppresses cancer stemness and metastasis in oral carcinomas stem cells through modulation of EMT. Oncotarget 2017;8:98542-98552.
Qiu JJ, Lin YY, Ye LC, et al. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. Gynecol Oncol. 2014;134:121–128.
Guo W, Dong Z, Bai Y, Guo Y, Shen S, Kuang G, et al. Associations between polymorphisms of HOTAIR and risk of gastric cardia adenocarcinoma in a population of north China. Tumour Biol. 2015;36:2845-54.
Yan R, Cao J, Song C, Chen Y, Wu Z, Wang K, Dai L. Polymorphisms in lncRNA HOTAIR and susceptibility to breast cancer in a Chinese population. Cancer Epidemiol. 2015;39:978–85.
Giuliano AE, Edge SB, Hortobagyi GNEighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Annals of Surgical Oncology 2018;25: 6797 • DOI: 10.1245/s10434-018-6486-6
30 Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. Breast Care 2013;8:149-54.
Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11:359-77.
Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, etal. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing inBreast Cancer: American Society of Clinical Oncology/College of American
Pathologists Clinical Practice Guideline Update. J Clin Oncol 2013; 31:3997-
4013.
Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Oncol Pract 2010; 6:195-7.
Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al;ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26:v8-30.
Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32–5
Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, et al. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Sci Rep. 2017;7:1089.
Bayram S, Sümbül AT, Dadaş E. A functional HOTAIR rs12826786 C>T polymorphism is associated with breast cancer susceptibility and poor clinicopathological characteristics in a Turkish population: a hospital-based case-control study. Tumour Biol. 2016;37:5577-84.
Hassanzarei S, Hashemi M, Sattarifard H, Hashemi SM, Bahari G, Ghavami S. Genetic polymorphisms of HOTAIR gene are associated with the risk of breast cancer in a sample of southeast Iranian population. Tumour Biol. 2017;39: 1010428317727539. doi: 10.1177/1010428317727539.
Copyright (c) 2020 Mohamed Elsammak, Ahmed Awad, Sarah Aglan, Omar Elsammak, Heba Gaber, Eman Elbakoury, Mohamed Hussein Sultan, Yasser Sayed Ahmed Hamed
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.